2026-525574-19-00RecruitingPhase 1
A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Eli Lilly & Co.
- Enrollment
- 16
- Locations
- 7
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Lilly Clinical Trials information desk
Scientific
Eli Lilly & Co.
Study Sites (7)
Loading locations...
Similar Trials
Recruiting
Phase 1
A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.Malaria2024-516911-26-00Novartis Pharma AG94
Completed
Phase 1
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zosurabalpin following Intravenous Administration in Healthy ParticipantsThere is no medical condition being investigated. This is a safety and pharmacokinetic study to be performed in healthy participants.2023-505411-20-00F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG30
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, and Activity of a Novel Oral Anticancer Drug (FLC‑436) in Patients With Refractory or Relapsed Solid MalignanciesRefractory or Relapsed Solid Malignancies2026-526215-10-00Fileclo Sp. z o.o.30
Recruiting
Phase 1
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COR-1389Obesity / Right heart failure (healthy participants)2024-514853-31-00Corteria Pharmaceuticals80
Suspended
Phase 1
A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusiveAutosomal Dominant Polycystic Kidney Disease2025-525073-37-00Glaxosmithkline Research & Development Limited30